Platelets - abnormal counts and cancer
Exam Tips
- Persistent thrombocytosis in adults >=40 years is an exam red flag for occult cancer even without classic alarm symptoms; repeat elevation increases post-test risk.
- The absolute platelet level alone does not reliably distinguish reactive from clonal thrombocytosis; trend, blood film, iron studies, and inflammatory markers are key.
- Always exclude pseudothrombocytopenia on blood film before escalating work-up (see blood film image of EDTA platelet clumping in haematology atlases).
- In thrombocytopenia OSCE stations, structure causes into reduced production, increased destruction, sequestration, and dilution.
- For pregnant patients >20 weeks with low platelets plus headache/visual symptoms/RUQ pain or hypertension, prioritise urgent assessment for pre-eclampsia/HELLP.
Definition
Abnormal platelet counts in oncology refer to thrombocytosis (platelets >450 x 10^9/L) or thrombocytopenia (platelets <150 x 10^9/L), interpreted in the context of possible malignancy, inflammation, marrow disease, or treatment effects. In UK primary care, persistent thrombocytosis is a red-flag laboratory finding for occult cancer (especially lung and colorectal), while thrombocytopenia in cancer often reflects marrow infiltration, chemotherapy/radiotherapy toxicity, immune destruction, or splenic sequestration.
Pathophysiology
Platelets are anucleate fragments from bone marrow megakaryocytes with a lifespan of about 7-10 days, central to haemostasis and immune-inflammatory signalling. In secondary thrombocytosis, inflammatory cytokines and thrombopoietic growth factors (for example IL-6-driven thrombopoiesis) increase platelet production; iron deficiency is a common UK cause. In malignancy, tumour-cell-induced platelet aggregation supports tumour survival in the circulation, endothelial adhesion, and metastasis, with thrombin-mediated positive feedback amplifying platelet activation. Thrombocytopenia arises through reduced production (marrow failure/infiltration, myelodysplasia, nutritional deficiency), increased destruction (immune, consumptive microangiopathy/DIC, drug-induced), sequestration (hypersplenism), or dilution; pseudothrombocytopenia from EDTA-dependent platelet clumping must be excluded on blood film.
Risk Factors
- Age >=40 years with new thrombocytosis
- Known or occult malignancy (particularly lung and colorectal for thrombocytosis)
- Chemotherapy or radiotherapy exposure
- Bone marrow disease (acute leukaemia, myelofibrosis, myeloproliferative neoplasm)
- Iron deficiency anaemia
- Chronic inflammatory disease (for example rheumatoid arthritis, SLE)
- Recent surgery, trauma, bleeding, or infection
- Previous splenectomy or functional hyposplenism
- Chronic liver disease/portal hypertension with hypersplenism
- Pregnancy (including risk of pre-eclampsia/HELLP after 20 weeks)
- Drug exposure (for example heparin, quinine/quinidine, NSAIDs, penicillins, anticonvulsants, corticosteroids)
- Alcohol excess and nutritional deficiency (vitamin B12/folate)
Clinical Features
Symptoms
- Often asymptomatic and found incidentally on FBC
- Constitutional cancer symptoms: weight loss, fatigue, night sweats
- Lung/GI alarm symptoms: unexplained cough, haemoptysis, change in bowel habit, rectal bleeding, dyspepsia >55 years, dysphagia
- Bleeding symptoms in thrombocytopenia: epistaxis, gum bleeding, menorrhagia, easy bruising, GI/GU bleeding
- Microvascular/thrombotic symptoms in thrombocytosis: headache, dizziness, visual disturbance, paraesthesia, chest pain, erythromelalgia, transient neurological symptoms
- Infection-related symptoms: fever, rigors, diarrhoea/vomiting
Signs
- Petechiae, purpura, ecchymoses, mucosal bleeding
- Pallor or clinical anaemia
- Lymphadenopathy or splenomegaly/hepatomegaly
- Signs of chronic liver disease (spider naevi, palmar erythema, ascites, oedema)
- Features of thrombosis/digital ischaemia
- Evidence of underlying inflammatory, rheumatological, or malignant disease
Investigations
Management
Lifestyle Modifications
- Address reversible contributors: reduce alcohol intake, optimise nutrition (including iron/B12/folate where deficient), and treat infection/inflammation promptly.
- Bleeding-risk advice in thrombocytopenia: avoid contact sports/IM injections where possible, use soft toothbrush/electric razor, and seek urgent care for severe headache, melaena, haematemesis, or persistent mucosal bleeding.
- VTE risk reduction in cancer: maintain mobility/hydration and follow oncology thromboprophylaxis plans.
Pharmacological Treatment
Treat reversible reactive causes
- Ferrous sulfate 200 mg orally once daily (approximately 65 mg elemental iron) for iron deficiency; continue for around 3 months after Hb normalises
- Alternative oral iron: ferrous fumarate 210 mg once daily or ferrous gluconate 300 mg once daily
Iron deficiency is a common cause of reactive thrombocytosis; counsel on GI adverse effects and interactions (for example with antacids/levothyroxine).
Antiplatelet/cytoreductive therapy in clonal thrombocytosis (specialist-led)
- Aspirin 75 mg orally once daily
- Hydroxycarbamide initially often 500 mg once or twice daily, then titrated to blood counts
- Interferon alfa (pegylated regimens) in selected patients, especially when pregnancy is relevant
Use under haematology guidance. Avoid aspirin with active major bleeding or very low platelets; hydroxycarbamide is teratogenic and myelosuppressive (requires frequent FBC monitoring).
Immune thrombocytopenia (including paraneoplastic immune mechanisms) - specialist care
- Prednisolone 1 mg/kg orally once daily (typical max 80 mg/day), then taper according to response
- Dexamethasone 40 mg orally once daily for 4 days (pulse regimen)
- Human normal immunoglobulin (IVIg) 1 g/kg/day for 1-2 days for severe bleeding or urgent platelet rise
- Eltrombopag 50 mg orally once daily (lower start in hepatic impairment/selected ethnic groups), adjusted to platelet response
- Romiplostim 1 microgram/kg subcutaneously once weekly, titrated to platelet count
Check bleeding severity and thrombotic risk together. Steroids increase infection/hyperglycaemia risk; IVIg can cause thrombosis/renal dysfunction; TPO receptor agonists carry hepatotoxicity and thrombosis warnings and require monitoring.
Chemotherapy-induced thrombocytopenia/supportive care
- Withhold, delay, or dose-reduce myelosuppressive systemic anticancer therapy per protocol
- Tranexamic acid 1 g orally three times daily (or IV equivalent) for clinically significant mucosal bleeding where appropriate
Coordinate with oncology. Avoid antifibrinolytics in active intravascular clotting unless specialist advised; review contraindications (history of thrombosis, haematuria source, renal impairment).
Surgical / Interventional
- Splenectomy for refractory immune thrombocytopenia after multidisciplinary specialist assessment.
- Urgent treatment of underlying malignancy (for example surgery for colorectal/lung cancer where stage-appropriate) to remove a driver of paraneoplastic platelet abnormalities.
- Platelet transfusion (procedural/supportive rather than surgical) for severe bleeding or peri-procedural thresholds as per local haematology protocol.
Complications
- Occult cancer diagnosis delay if persistent thrombocytosis is not investigated
- Venous thromboembolism and arterial thrombosis (stroke, myocardial infarction, digital ischaemia)
- Major haemorrhage, including gastrointestinal or intracranial bleeding in severe thrombocytopenia
- Treatment complications: infection and metabolic effects from steroids, cytopenias from myelosuppressive therapy, drug-induced liver toxicity
- Pregnancy morbidity with HELLP/pre-eclampsia-associated thrombocytopenia
Prognosis
Prognosis depends on cause and speed of identification. Reactive platelet abnormalities often improve when the trigger is treated, whereas clonal marrow disease and advanced malignancy carry persistent thrombotic/bleeding risk. In UK primary care cohorts over 40 with thrombocytosis, short-term cancer detection risk is clinically significant and rises further when thrombocytosis persists on repeat testing, supporting early investigation and referral.
Sources & References
✅NICE Guidelines(1)
- Platelets - abnormal counts and cancer[overview]
📖Textbook References(20)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 589, 590)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1617)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1617)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1391)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1601)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1317, 1318)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1618)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1658)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 914)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 914, 915)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2657)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 3168)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2909, 2910)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2397, 2398)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2909, 2910)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2655, 2656)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 3169)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 433)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 373)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 184)[context]